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Ultra-rapid, sensitive and speciﬁc digital diagnosis of HIV with
a dual-channel SAW biosensor in a pilot clinical study
Eleanor R. Gray 1, Valérian Turbé1,2, Victoria E. Lawson3, Robin H. Page3, Zara C. Cook3, R. Bridget Ferns4,5, Eleni Nastouli5,
Deenan Pillay4,6, Hiromi Yatsuda3,7, Dale Athey3 and Rachel A. McKendry1,2
Despite widened access to HIV testing, around half of those infected worldwide are unaware of their HIV-positive status and linkage
to care remains a major challenge. Current rapid HIV tests are typically analogue risking incorrect interpretation, no facile electronic
data capture, poor linkage to care and data loss for public health. Smartphone-connected diagnostic devices have potential to
dramatically improve access to testing and patient retention with electronic data capture and wireless connectivity. We report a
pilot clinical study of surface acoustic wave biosensors based on low-cost components found in smartphones to diagnose HIV in
133 patient samples. We engineered a small, portable, laboratory prototype and dual-channel biochips, with in-situ reference
control coating and miniaturised conﬁguration, requiring only 6 µL plasma. The dual-channel biochips were functionalized by ink-
jet printing with capture coatings to detect either anti-p24 or anti-gp41 antibodies, and a reference control. Biochips were tested
with 31 plasma samples from patients with HIV, and 102 healthy volunteers. SH-SAW biosensors showed excellent sensitivity,
speciﬁcity, low sample volumes and rapid time to result, and were benchmarked to commercial rapid HIV tests. Testing for
individual biomarkers found sensitivities of 100% (anti-gp41) and 64.5% (anti-p24) (combined sensitivity of 100%) and 100%
speciﬁcity, within 5 min. All positive results were recorded within 60 s of sample addition with an electronic readout. Next steps will
focus on a smartphone-connected device prototype and user-friendly app interface for larger scale evaluation and ﬁeld studies,
towards our ultimate goal of a new generation of affordable, connected point-of-care HIV tests.
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INTRODUCTION
The United Nations Sustainable Development Goals herald a
major commitment by the world to halt the spread of HIV/AIDS by
2030.1 Yet despite huge advances in testing and antiretroviral
therapy, around half of the estimated 37 million people living with
HIV in the world do not know their HIV-positive status,2,3 leading
to late presentation complicated by signiﬁcant immunosuppres-
sion, opportunistic infections and related mortality,4 and con-
tributing to the spread of HIV in the community.5,6 Pilot studies
have shown that widening access to testing, through placing
testing sites in locations such as community centres and money
transfer shops, is key to reaching sections of the population who
would not normally encounter HIV testing through traditional
services.7 Moreover, self-testing is now acceptable, feasible, and
has been made legal in some countries with internet and
smartphone-based apps under development to facilitate testing
and linkage to care.8,9 Patients can only engage with care if they
are aware of their HIV status. Diagnosis early in infection carries
signiﬁcant beneﬁts of increased life-expectancy by 10 years and
facilitates access to treatment, for example, reducing the risk of
mother to child transmission to under 1% whereas late diagnosis
carries an increased risk of onwards transmission and death.
Therefore widening access to diagnosis is a priority, alongside new
strategies to link patients to care.5,10–12
Worldwide, the most common rapid HIV tests are based on
lateral ﬂow immunochromatography, similar to pregnancy tests.
They are low cost but suffer from a number of key limitations.
Firstly, although they are rapid compared to gold-standard
laboratory-based tests, most require longer than 10min to
perform and cannot be run within a typical appointment with a
general practitioner in the UK.13 Interpretation is not trivial, as
even healthcare workers who daily administer rapid tests can
exhibit repeated operator errors that lower sensitivity and
speciﬁcity, such as reading tests before the stated time period
necessary for accurate interpretation has passed, and mis-reading
of faint bands.14,15 Most rapid tests in current use are entirely
analogue by design, without automated electronic data capture,
risking data loss and errors in manual entry of data. Only a few are
compatible with an automated reader, which removes the need
for user interpretation but doesn’t reduce the time to result or
automate long-term recording of results into electronic medical
records.16,17 There is no automated follow-up of patients, leading
to potential for loss through the care cascade.10,18 Moreover, the
advent of self-testing leads to an increase in ﬁrst-time users
without extensive training. A study showed that only 26% of
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naïve, ﬁrst-time self-testers correctly interpret weakly reactive
tests.15
Smartphones have come to the fore in recent years as tools to
facilitate access to and widen capabilities of rapid diagnostic
devices, using the inbuilt sensors and computational power of the
device, or their ability to wirelessly link results to public health
systems.19 The smartphone camera can be used in conjunction
with algorithms to analyse results of lateral ﬂow test strips, and the
battery of phones has been used to power a microﬂuidic dongle
attachment for dual HIV-syphilis tests.20–23 Key research chal-
lenges include compliance with target product proﬁle guidelines
for suitable characteristics of an HIV rapid test set out by the
Programme for Appropriate Technology in Health (PATH) such as
a closed system, and fewer than three steps.
Here we report on the development of a digital diagnostic
device based on shear horizontal surface acoustic wave (SH-SAW)
biosensors and a clinical pilot study of this biosensor to detect HIV
with 133 patient samples. The principle of SH-SAW dates back to
Lord Rayleigh in 1885, with the ﬁrst sensing application reported
in 1979,24 and the ﬁrst application as a biosensor in 1983.25 For
decades, a key challenge facing the ﬁeld for biosensing
applications was the compatibility of liquid samples with SH-
SAW electrical components.26 A breakthrough came through the
engineering of microfabricated SH-SAW chips with a glass-
polymeric capping layer to protect interdigitated electrodes,
making them compatible with complex biological samples,
without the need to use complex microﬂuidics which can clog.27
The SH-SAW biosensors described herein utilise microelectronic
components to detect multiple patient HIV antibodies without
additional complexity of washing or component labelling—
technology which has the potential to advance to the next
generation of ASSURED biosensors for disease diagnostics.28 SH-
SAW sensors are suitable for economic mass manufacture, costing
ca. $1.50 for each disposable biochip and can quantitatively detect
the binding of proteins to their surface.29 They have been used
with a wide range of sample types in a variety of media to detect,
for example, bacteria in micro-volumes,30 cellular interactions,31
DNA32 and have also been used as biosensors for the detection of
antibodies to viral pathogens in blood.33 In addition, unlike lateral
ﬂow tests, the readout provided by SH-SAW biosensors is entirely
electronic, thereby avoiding the risk of incorrect interpretation of
the test result. The absence of need for interpretation of the test
result, simplicity of use, low cost and user-friendly presentation of
the test result are key points that form part of the target product
proﬁle for HIV self-tests set out by PATH.34 The electronic readout
can be carried out by a smartphone app (prototype in
development), which could help to widen access to testing given
the ubiquity of smartphones, particularly amongst hard to reach
groups such as young people.35 The app could also be used to
initiate follow up appointments, closing a gap in the care
cascade.9
Herein we report on a number of signiﬁcant technical
developments, which builds on our previous proof of concept
work using puriﬁed antibodies to HIV in buffer samples36; (i) A new
dual-channel biochip with in-situ reference to improve speciﬁcity.
Our previous study utilised two manually functionalized indepen-
dent biochips; a detection biochip and reference biochip.36
Although this study highlighted the potential of the technology,
the use of separate biochips posed challenges as each biochip was
constructed on a separate piezoelectric crystal and functionalized
manually. This could lead to inter-chip variation, and failure to
accurately control for non-speciﬁc effects when samples or
volumes differ across two biochips. Here, the biochips have been
signiﬁcantly improved with multiple channels on a single biochip,
with an in-situ reference channel to account for non-speciﬁc
signals, for example, from sample viscosity; (ii) Miniaturized device
conﬁguration requiring smaller sample volumes. The SH-SAW
biosensors used in this study require just 6 µl sample in
comparison to the previous device which required 20 µl, bringing
the volume within the ‘optimistic’ target range speciﬁed by PATH
(10 µl).34 A smaller sample makes the test less invasive for those
who ﬁnd it difﬁcult to produce large or multiple blood drops (such
as neonates or the elderly), and a miniaturized device uses less
raw material, lower costs, and less waste; (iii) Biochip functiona-
lization via inkjet printing amenable to mass manufacture.
Automation of biochip preparation removes variation in chip
preparation steps, increases homogeneity of chips, and therefore
consistency of results in comparison to manually prepared
biochips; (iv) Detection of multiple HIV biomarkers to increase
speciﬁcity and sensitivity. Our previous study focused on
detection of anti-p24 antibodies alone. Here we also detect anti-
gp41, which is the ﬁrst antibody biomarker of HIV infection,
opening up the possibility of earlier diagnosis of HIV. We
investigated the sensitivity and speciﬁcity of both biomarkers,
and combined sensitivity and speciﬁcity when both biomarkers
are used, since case studies have reported the absence of anti-
gp41 antibodies among a small number of patients37,38; (v) Pilot
clinical study with 133 patient samples. Our previous study largely
focused on recombinant proteins in buffer solution, and testing of
one HIV positive patient sample and one healthy volunteer,
insufﬁcient to determine the clinical sensitivity and speciﬁcity. By
contrast, here we test 133 samples, 31 from patients with HIV, and
102 healthy volunteers; (vi) Analysis of biochip variation. We
present head to head results from two biochips for each HIV-
positive sample; (vii) Benchmarking to leading commercial rapid
tests. We compared the performance of SH-SAWs to leading rapid
index tests in terms of sensitivity, speciﬁcity, sample volume, time
to result and electronic data capture.
RESULTS
Dual-channel biochips with an in-situ reference channel to
increase speciﬁcity
The underlying principles of SH-SAW biosensors and their
application to the development of rapid HIV tests to detect
analytes in biological samples was described in the refs.3936 In
brief, SH-SAW biochips comprise a sensing area with waterproof
electrodes at one end. This sensing area is sensitive to biological
binding events. Figure 1a–c shows the key components used in
this study. A schematic of the SH-SAW biochips is shown in Fig. 1a
and Supplementary Figure 1, with the two channels and different
coatings of each channel represented by symbols. The actual
biochips used are shown in Fig. 1b, where the channels and
electrodes are surrounded by a black resin to contain liquid
samples. Electrodes are protected by a glass lid. An image of a
prototype reader used for the experiments described in this paper
is shown in Fig. 1c, which was connected to a laptop.
The biochip reference channel was coated with an artiﬁcial
synthetic protein that is designed to be completely unlike any
human or animal protein (non-animal protein, NAP), and only non-
speciﬁc binding and a signal change due to the viscosity of the
sample placed on the chip will be recorded on this channel. The
signal from this reference channel can be used to compensate for
non-speciﬁc effects in the ‘antibody-detection’ channel by
calculation (i.e., ‘antibody-detection’ channel minus reference
channel). This permits SH-SAW biochips to be used with a wide
range of sample types with varied viscosities such as blood or
serum.
Two antibody detection channel coatings were used to capture
either anti-gp41 or anti-p24. Anti-gp41 is usually the ﬁrst antibody
to appear after HIV infection and therefore a key immune marker
of HIV infection (Supplementary Figure 2 and ref. 40). Inkjet
printing automates biochip channel preparation, marking an
important step towards an efﬁcient and cost effective
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manufacturing, and improving on the previous generation of
biochips which were manually functionalized.36
The SH-SAW chips were initially stored unfunctionalized for
several months at room temperature. After biochips were
prepared by functionalization, they were stored at 4 °C (with
desiccant) for one to two weeks until analysis. During a sample
run, biochips were equilibrated in 6 μl Tris-buffered saline with
0.5% Tween-20 for 30 s to ensure that they were responding
normally after placement in the biochip holders. After 30 s, the
buffer was removed and 6 μl sample added. An example of a raw
data readout from a single HIV-positive and a single HIV-negative
sample run on two separate biochips each detecting anti-gp41 is
shown in Fig. 2a, i, ii respectively, and for anti-p24 in Fig. 2b, i, ii
respectively. The differential signal generated by subtracting the
reference channel from the antibody detection channel gives the
assay output, reported as differential SH-SAW reading (Fig. 2a, i).
Pooled conﬁrmed negative donor samples were spiked with
puriﬁed human anti-HIV antibody at concentrations ranging
between 0 and 100 μg/ml to validate biochip preparation and
assay viability. Raw data readouts from runs with 25 and 0 µg/ml
antibody are shown for anti-gp41 in 2a, iii and 2a, iv respectively,
and for anti-p24 in 2b, iii and 2b, iv respectively. All calibration
data are shown in Supplementary Figure 3. From these spiked
calibration samples, preliminary limits of detection can be
calculated for anti-p24 of 22.2 µg/ml, and anti-gp41 of 25.5 µg/ml.
Pilot study of clinical sensitivity and speciﬁcity
Assays were run for 31 patient samples in duplicate, 98 healthy
donors once, and four healthy donors twice, all for anti-gp41 and
anti-p24 biochips. The differential signal for each run is plotted in
Fig. 3a separately for anti-gp41 and anti-p24 readings. A sample
was considered positive if the differential reading values for either
or both of the anti-gp41 and anti-p24 biochips was above the
threshold, and negative only if both readings were below the
thresholds (Fig. 3a, green lines, and Supplementary Table 1). For
anti-gp41, the threshold was deﬁned as the mean plus four times
the standard deviation of the mean of the differential signal from
repeated pooled negative samples, and for anti-p24, plus ﬁve
times this value; these values were chosen to position all negative
results below the cut-off. Average HIV-positive test results above
this threshold were considered positive, and under this threshold,
negative. All of the samples from patients with HIV gave a true
positive average reading for anti-gp41 detection, giving a
sensitivity of 100% for this part of the test alone (Fig. 3a). For
anti-p24 detection, 20 samples gave average true positive
readings, and 11 gave an average false negative reading, giving
a sensitivity of 66.1%. Overall, therefore, the combined sensitivity
was 100% as deﬁned by a positive reading for one or both anti-
gp41 and anti-p24 biomarkers (Table 1 and Supplementary Table
1). Samples were run in duplicate to assess biochip variation
(Supplementary Figure 4); results from the two runs were not
signiﬁcantly different (p= 0.99, t-test).
Neither anti-p24 nor anti-gp41 markers were detected in any of
the healthy donor samples, giving a speciﬁcity of 100% of
detection for both antibodies (Fig. 3a).
Time to result
In order to assess the speed of the assay, the time for the
differential signal to cross the cut-off threshold was plotted for
anti-gp41 or anti-p24 (Fig. 3b). All of the positive samples had
given a true-positive readout for anti-gp41 within 60 s (Fig. 3b, i,
grey line). After ﬁve minutes, all the negative donor samples had
remained negative (Fig. 3b, ii, shown in duplicate inset on an
enhanced scale).
Comparison to commercial rapid HIV tests
The samples from the patients with HIV were from patients with
viral loads of at least 5,000 copies/mL, obtained at the stage of
discard by the laboratory, and had been kept at 4 °C for three
weeks. It is unclear what effect this might have on the samples
although degradation, rather than the opposite, is probable. In
order to validate the results obtained from the antibody portion of
the test, the samples were therefore also run on two commercially
available point-of-care (POC) index tests; the Alere HIV-1/2 Ag/Ab
Combo, and the OraQuick Advance. These two were in use in the
UK at the time of our study, and the OraQuick Advance is also sold
as an HIV self-test in the US, though other, faster rapid tests are
now available (for example, the Pasante Insti). The results of these
Fig. 1 SH-SAW biosensor and biochips. a Key characteristics of dual-channel biochips. b Dimensions of disposable laboratory-use biochips.
Channels are surrounded by black resin, with electrodes under glass protection. c Laboratory-based biochip holders and prototype reader
(biochips in b are beneath metal covers). This was the reader used in this study. White scale bar shows 2 cm
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rapid tests with the samples used in this study are shown in Table
2. All HIV enzyme immunoassay-positive samples gave clear
positive antibody readings on both the Alere HIV-1/2 Ag/Ab
Combo and the OraQuick Advance tests. None of the HIV-positive
samples gave a positive p24 antigen reading using the Alere HIV-
1/2 Ag/Ab Combo test, but a positive antigen result was not
expected given that the samples are from patients who have
probably seroconverted. The two commercial rapid tests both
detect anti-gp41, which was also positive in all samples by the SH-
SAW assay. These results verify the validity of the results for anti-
gp41 obtained using the SH-SAW biochips.
DISCUSSION
Our ﬁndings highlight the potential of SH-SAW biosensors with
dual-channel biochips to detect the presence of anti-HIV
antibodies at clinically-relevant levels, with 100% sensitivity and
100% speciﬁcity, within very short (60 s) timescales at low (6 μl)
sample volumes. With further development into a fully user-
friendly, sample-preparation free smartphone-connected format,
SH-SAW biosensors have potential as a foundation for the next
generation of low cost (ca. $1.50 for disposable components),
rapid, POC screening tests. These performance characteristics
align to the World Health Organisation’s target product proﬁle for
upcoming HIV rapid tests that have the potential to facilitate the
transformation of testing, enabling it to stand apart from
traditional healthcare settings and trained workers, and empow-
ering patients themselves in non-traditional settings (Supplemen-
tary Table 2 and http://www.idc-dx.org/resources/target-product-
proﬁle-hiv-self-test). An optimal POC test requires no sample
preparation steps, minimal input and interpretation required from
the user, would link the patient directly into healthcare services
with wireless connectivity and yet would operate with the same
sensitivity and speciﬁcity as those currently available for profes-
sional healthcare workers.
The 100% sensitivity for anti-gp41 and 100% speciﬁcity
achieved in this small pilot study is promising. Next steps will
focus on testing whole blood with a larger number of patient
Fig. 2 Raw signal readout from anti-gp41 and anti-p24 biochip individual runs. Shown are reference (dashed lines) and analyte (continuous)
channels for a anti-gp41 and b anti-p24 biochips; (i) a single HIV-positive sample, two biochips; (ii) a single healthy donor sample on two
biochips; for calibration samples at (iii) 25 μg/ml; and (iv) 0 μg/ml. The differential signal is indicated in a (i) (analyte minus reference channels)
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samples, the development of a ﬁnal cartridge format and
smartphone connected prototype, amenable to ﬁeld usage, and
longevity studies of biochip shelf-life at a variety of different
temperatures and time-scales. A ﬁnal cartridge format will be
required to omit the buffer stabilisation steps used herein, and the
encasement of the SH-SAW biochip entirely in plastic to ensure
that the chip is not ﬂooded by an average drop of sample
(20–50 µl). The detection of two antibodies either on a single test
channel or separately on two ensures that sensitivity will remain
high in sporadic cases of patients with low reactivity to gp41
antigen.37,38 During the course of this project multi-channel
biochips have been designed which means that the two tests
described here could be combined on one biochip, and eventually
multiplexed with additional channels. Ideally, a channel would be
dedicated to a target of acute HIV infection, such as p24 antigen
or RNA, to permit diagnosis of those at an early stage after
transmission. Alternatively, tests for other blood-borne diseases
could be incorporated to enable a general ﬁrst-line screening tool,
as a multiplexed blood-borne panel (see, for example ref. 23).
This small study used samples that were at the stage of discard
from the diagnostic laboratory and had been stored for three
weeks between receipt and discard. It was not possible to know at
which stage of infection the patients were at the time of sampling,
though as they had viral loads of at least 5000 copies/mL it is not
probable that they were taking effective antiretroviral therapy. It is
possible that they were recently diagnosed, however, all had
seroconverted and were reactive by two third generation rapid
antibody tests, making this scenario unlikely. The enzyme
immunoassay used at UCLH to initially determine the status of
the samples does not discriminate between antigen-positive and
antibody-positive, and the two rapid tests used in this study
detect anti-gp41 and not anti-p24. There is therefore no guarantee
that these samples were assuredly anti-p24 positive. Usage of
many more negative samples with an appropriate sample size
calculation would also permit reﬁnement of the cut-off value, as
well as a more accurate characterisation of the speciﬁcity of the
SH-SAW biosensor. Nevertheless, the levels of sensitivity achieved
remain promising. For the purposes of this initial pilot study with
patient samples, we note that we have used only plasma samples
taken from routine submissions for viral load testing at University
College London Hospital (UCLH) at the point of discard, when they
had been already separated into plasma and cellular matter for
storage. Future studies will be performed in a larger trial using
freshly drawn whole blood and potentially other sample types
such as saliva.
During this study we used a laboratory prototype SH-SAW
biochip reader connected to a laptop (Fig. 1c). A prototype
consumer unit (handheld reader controlled by a smartphone app
and disposable cartridge, Supplementary Figure 5) has been
made, which contains the same SH-SAW biochip components as
the laboratory prototype, and the ability to transfer test results via
Bluetooth to the smartphone. The SH-SAW biochip in the
disposable cartridge is hidden under the plastic coating, is
designed for use with whole blood without sample preparation,
and is self-contained and entirely disposable which limits the
potential for contamination. Challenges of moving to the next
stage of development will include: (i) Moving the test outside the
laboratory environment, where temperature, humidity, and dust
levels will be variable; (ii) Working directly with freshly drawn
whole blood, with samples of variable haematocrit; (iii) Testing of
Fig. 3 Combined biochip data. a Differential signals for 31 HIV-
positive (duplicate averages) and 102 healthy volunteer samples on
anti-gp41 and anti-p24 biochips. Means are shown with standard
deviations for each group. Green lines, positive threshold cut-offs. b
(i) Time-resolved sensitivity for HIV-positive samples. By 53 s (grey
marker) all positives gave a reactive result. (ii) Time-resolved
speciﬁcity data. After 5 min, all negative samples gave negative
results. Inset: Enlarged Y-axis view
Table 1. Collated results for the SH-SAW biochips on conﬁrmed HIV-positive and HIV-negative samples
HIV positive samples HIV negative samples Sensitivity (%) Speciﬁcity (%)
Total TP FN Total TP FN
Anti-gp41 31 31 0 102 102 0 100 100
Anti-p24 31 20 11 102 102 0 64.5 100
Combined 31 31 0 102 102 0 100 100
Sensitivity and speciﬁcity were calculated for the average results for either anti-gp41 or anti-p24 individually and in combination. If a sample gave a positive
result for either analyte, it was deemed positive, but must be negative for both analytes to be considered negative
TP true positive, FN false negative, FP false positive, TN true negative
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SAW biochips with low levels of haemolysis, which can occur
subsequent to ﬁnger prick blood draw; (iv) Addition of samples
without pipettes directly from patients, with non-quantiﬁed and
differing volumes of blood; (v) Training requirements for usage of
the test by non-laboratory staff. Prototype consumer units in
development utilise a variety of approaches to handle whole
blood samples. One approach that has been investigated is the
use of a membrane to retain red blood cells, while allowing the
liquid fraction of plasma to migrate through to the SAW biochip.
This takes place inside the test cartridge, with limited opportunity
for interference or complexity for the user. We aim to use
feedback from preliminary trials with inexperienced users to reﬁne
instructions, training and the user interface. Parallel to these will
be the general challenges of implementation in settings where
patients come for POC HIV testing, and integration of the
technology into existing clinical pathways. Close partnerships
between the product development and manufacturing teams, as
well as clinical collaborators and end-users during development
will ensure that the technology developed is suited to the speciﬁc
needs of end-users. Future work will focus on testing the
performance of this prototype in the following areas that will be
key for clinical adoption: evaluate our prototype using perfor-
mance panels representative of the existing diversity of HIV
subtypes worldwide; evaluate performance with different types of
specimens that will aid use in the ﬁeld (i.e., ﬁnger prick whole
blood and saliva); test an extended number of patients
prospectively in a ﬁeld study by healthcare workers and also
potentially self-testing. Data transfer through an electronic
programme such as an app permits future connectivity of results
to public health data systems
To close, our ﬁndings lay the foundation for a new paradigm of
digital diagnostic technology that combines all of the beneﬁts of
current rapid HIV tests based on lateral ﬂow (cost, time to result,
simplicity of use) with the additional beneﬁts of electronic data
capture, no user-interpretation, geo-located connectivity, and the
ability to link the patient into care, supporting faster access to
treatment and counselling for those who test both positive and
negative.
METHODS
Recombinant antigen and puriﬁed antibody
Recombinant p24 and gp41 were obtained from Capricorn Bioproducts
(USA) and Fitzgerald Industries (USA) respectively. Puriﬁed human anti-HIV-
1 antibody was obtained from ImmunoDX (USA). All reagents were stored
and processed according to the manufacturer’s recommendations.
SH-SAW Biochip preparation
SH-SAW biochips are described in the ref. 39,41 and biochip manufacture
was performed essentially as described in the ref. 36 Brieﬂy, biochips were
based on a quartz crystal (36°Y-cut 90°X-propagation) operating at a
frequency of 251.5 MHz. Gold interdigitated transducers were evaporated
onto the crystal, consisting of 80 ﬁnger pairs with an aperture of 1 mm.
Two nanometre thin ﬁlm titanium, then 90 nm thin ﬁlm gold was
evaporated in between the interdigitated transducers, which were
protected from liquid by a glass lid an epoxy walls, as described in the
ref. 27 Biochips used here were a later version with dual channels. Biochip
preparation was performed essentially as described in the ref. 36 Brieﬂy,
biochips were cleaned with 2% Hellmanex™, functionalized using 4mg/ml
dithiobis(succinimidyl propionate) and channel-speciﬁc capture protein
using an automated Musashi Jet Spotter platform. For this study, dual
channel biochips were prepared with non-animal protein (NAP, G-
Biosciences, USA) on the reference channel and recombinant gp41 or
p24 antigen on the detection channel. Biochips were dried under a stream
of N2, and stored at 4 °C with desiccant until use.
SH-SAW assays
SH-SAW chips were made in batches of 200–400 chips; quality control
criteria required an insertion loss in air of between 21 and 22 dB. SH-SAW
biochips with a dual channel (reference and test channel) were used with
6 µl sample for each biochip run, which is the maximum load of the
biochips. The biochip surface is covered with approximately 4 µl, after
which the measurement is insensitive to changes in volume. Phase shift,
which indicates levels of bound biological matter, was recorded every
second for 30 s after buffer addition, and then for up to 5min after buffer
removal and sample addition. The change in phase shift attributed to
sample antibody binding was calculated from the sample (detection)
channel after subtracting the signal from the reference NAP channel. A
quality control calibration curve was run prior to sample testing to ensure
functional biochip preparation for the batch using 0, 10, 25 and 100 μg/ml
puriﬁed human anti-gp41 or anti-p24 antibody (diluted in negative pooled
plasma).
Point-of-care (POC) tests
All tests were run as per the manufacturers’ instructions for stored plasma
samples, and readout results were combined from two independent
operators.
Plasma samples
Pooled HIV-negative plasma samples, and individual negative samples
from screened commercial donors were obtained from Lee Biosolutions
(USA) in January 2016. These samples were screened for HIV by FDA-
approved methods. HIV-negative samples were also taken after informed
consent was obtained from healthy volunteers of UCL staff and students
between November to December 2015. HIV-positive samples were
collected from consecutive patients attending UCLH HIV services over a
period of a month within September to October 2014 who had a viral load
of over 5000c/mL (using an in-house assay), and were anonymized and
retained after clearance for discard from UCLH diagnostic laboratory. Aside
Table 2. A comparison of test characteristics and results for the OJ-Bio SH-SAW test and two commercial POC HIV-1 index tests
Sample OJ-Bio SH-SAW biosensor OraQuick Advance HIV-1/2 Alere determine HIV-1/2 Ab/Ag Combo
Antibody/Antigen (Ab/Ag) Ab Ab Ab
Biomarker targets Anti-gp41
Anti-p24
Anti-gp41 Anti-gp41
All HIV-positive samples + + +
All healthy donor samples – – –
Pooled donor plasma – – –
Volume of sample required (μl) 6 2.5 50
Time to result (min) 5 20 20
Electronic data capture and connectivity Inbuilt None None
Shown is a summary of results from the pilot clinical study in comparison to results obtained from two currently available POC tests in the UK for samples used
in this study. Ab, antibody; Ag, antigen. See Table 1 and Supplementary Table 1 for numbers and results of samples tested on the SH-SAW biosensors
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from the viral load, no further eligibility criteria were imposed. All samples
were aliquotted upon receipt and stored at −80 °C until use (up to
18 months).
Cut-off calculation
Repeat negative samples (pooled negative donor) were run to calculate an
upper readout value under which 99.99%, or over 99.99%, of the negative
samples would be contained (the mean plus four times and ﬁve times the
standard deviation of the results from pooled negative samples for anti-
gp41 and anti-p24 respectively). This was chosen as a cut-off threshold.
Average HIV-positive test values above this limit were considered true
positives, and values below this, false negatives.
Ethics statement
The HIV enzyme immunoassay-positive samples were anonymized and
had clearance for discard from the UCLH diagnostic laboratory. They were
collected as part of the ICONIC project, approved by the Ethical Committee
NRES Committee London - Surrey Borders HRA, Research Ethics Committee
(REC) London Centre Study title: InfeCtion respONse through vIrus
genomiCs (ICONIC) REC reference:13/LO/1303. HIV viral load was above
5000 c/mL. Samples obtained from UCL staff and students were taken after
full informed consent was given. The study was reviewed by UCL Ethics
Board and given study number 6109/001.
Data availability
The datasets generated and analysed during the current study analysis is
available from the corresponding author on reasonable request.
Code availability
Custom Mathematical code used for analysis is available from the
corresponding author on request.
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